Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

International Prognostic Score (IPS) for Hodgkin Lymphoma

The IPS identifies 7 adverse prognostic factors for advanced Hodgkin lymphoma, predicting freedom from progression to guide treatment intensity decisions.

Evidence-based context for fast calculator use

Purpose:
Predict prognosis in advanced-stage Hodgkin lymphoma (stages III-IV)
Population:
Patients with advanced Hodgkin lymphoma (stage III-IV or bulky stage II)
Factors:
Age ≥45, Male sex, Stage IV, Albumin <4 g/dL, Haemoglobin <10.5 g/dL, WBC ≥15,000, Lymphocyte count <600 or <8%
Reference:
Hasenclever & Diehl, NEJM 1998
HomeIPS (Hodgkin Lymphoma)
Pin your most used calculators here by clicking the star in the dropdown.

IPS (Hodgkin Lymphoma)

Clinical Context & Background

The International Prognostic Score (IPS) predicts 5-year progression-free and overall survival in patients with advanced stage (III/IV) Hodgkin Lymphoma. It counts 7 adverse risk factors.
Primary Source EvidenceHasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339(21):1506-1514.
Formula Logic
Sum of 7 risk factors (Age, Stage, Hb, Albumin, WBC, Lymphopenia, Male).

Reference Data

Total Score5-Year Freedom From Progression (FFP)
084%
177%
267%
360%
451%
≥ 542%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use IPS (Hodgkin Lymphoma) when iPS (Hasenclever) predicts progression-free survival in advanced Hodgkin lymphoma to guide escalation of first-line chemotherapy regimens.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning 0 through ≥ 5.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm morphology, molecular/cytogenetic data, treatment timing, laboratory units, and the current disease-specific guideline before acting.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Hematology scores are diagnosis-, phase-, and treatment-specific and should not be transferred between diseases.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with the specific hematologic diagnosis and disease phase described by the model

How to apply this result

For a representative case, verify Age ≥ 45 years?, Sex, Stage IV Disease?, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Hematology hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

NCCN-IPI (Lymphoma)CLL-IPIMIPI (Mantle Cell Lymphoma)

Frequently Asked Questions

When should IPS (Hodgkin Lymphoma) be used?

Use it for patients with the specific hematologic diagnosis and disease phase described by the model when all required inputs and the intended clinical setting are confirmed.

Can IPS (Hodgkin Lymphoma) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.